3rd Annual CKD3 Summit

March 2 - 4, 2021 - KS US

Hanson Wade


Overcome the translational challenges limiting the development of the next generation of CKD therapeutics. For the 3rd year, the Chronic Kidney Disease Drug Development Summit (CKD3) is putting the hottest topics in CKD drug development under the spotlight. Addressing questions including: what are the mechanisms driving the beneficial effects in SGLT2 inhibition, how is pharma harnessing the power of AI and what kidney organoids are providing innovation to target identification: CKD3 is the definitive, intimately focused forum promoting cross stakeholder discussion and networking to accelerate the next line of CKD drugs. Built with insight from 30+ kidney heavy weights including Reata Pharmaceuticals, AstraZeneca, Goldfinch Bio and Boehringer Ingelheim, the 3rd CKD3 Summit will comprehensively analyze the challenges in CKD drug development from genetics to costing, providing the thought-leading synthesis of all the information you need to accelerate meaningful therapeutics to renal disease patients.

More Information